相似文献
1
ST2: the biomarker at the heart of GVHD severity.
Blood. 2015 Jan 1;125(1):10-1. doi: 10.1182/blood-2014-11-611780.
2
High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation.
Blood. 2015 Jan 1;125(1):199-205. doi: 10.1182/blood-2014-06-584789. Epub 2014 Nov 6.
3
One-unit versus two-unit cord-blood transplantation for hematologic cancers.
N Engl J Med. 2014 Oct 30;371(18):1685-94. doi: 10.1056/NEJMoa1405584.
4
The IL-33/ST2 axis augments effector T-cell responses during acute GVHD.
Blood. 2015 May 14;125(20):3183-92. doi: 10.1182/blood-2014-10-606830. Epub 2015 Mar 26.
5
Systemic biomarkers of allogeneic haematopoietic stem cell transplantation outcome-Brief introduction.
HLA. 2019 Dec;94 Suppl 2:25-29. doi: 10.1111/tan.13761.
6
Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
Haematologica. 2016 May;101(5):634-43. doi: 10.3324/haematol.2015.138594. Epub 2016 Feb 11.
7
Tear Cytokines as Biomarkers for Chronic Graft-versus-Host Disease.
Biol Blood Marrow Transplant. 2015 Dec;21(12):2079-2085. doi: 10.1016/j.bbmt.2015.08.020. Epub 2015 Aug 22.
8
Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide.
Haematologica. 2017 May;102(5):932-940. doi: 10.3324/haematol.2016.152322. Epub 2017 Jan 25.
9
Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation.
Biol Blood Marrow Transplant. 2016 Nov;22(11):2025-2030. doi: 10.1016/j.bbmt.2016.08.005. Epub 2016 Aug 9.
10
Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies.
Transplant Proc. 2007 Jun;39(5):1615-9. doi: 10.1016/j.transproceed.2006.12.042.
引用本文的文献
1
Graft-Versus-Host Disease: Can Biomarkers Assist in Differential Diagnosis, Prognosis, and Therapeutic Strategy?
Pharmaceuticals (Basel). 2024 Feb 26;17(3):298. doi: 10.3390/ph17030298.
2
Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants.
Front Immunol. 2024 Feb 16;15:1327035. doi: 10.3389/fimmu.2024.1327035. eCollection 2024.
3
A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.
PLoS One. 2021 Jun 25;16(6):e0252995. doi: 10.1371/journal.pone.0252995. eCollection 2021.
4
Extracorporeal Photopheresis (ECP) and the Potential of Novel Biomarkers in Optimizing Management of Acute and Chronic Graft vs. Host Disease (GvHD).
Front Immunol. 2020 Jan 31;11:81. doi: 10.3389/fimmu.2020.00081. eCollection 2020.
5
Seeking biomarkers for acute graft-versus-host disease: where we are and where we are heading?
Biomark Res. 2019 Aug 7;7:17. doi: 10.1186/s40364-019-0167-x. eCollection 2019.
6
Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution.
Oncotarget. 2018 Nov 2;9(86):35611-35622. doi: 10.18632/oncotarget.26242.
7
Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD.
Bone Marrow Transplant. 2017 Oct;52(10):1399-1405. doi: 10.1038/bmt.2017.119. Epub 2017 Jun 26.
8
Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease.
Biol Blood Marrow Transplant. 2017 Aug;23(8):1257-1263. doi: 10.1016/j.bbmt.2017.04.029. Epub 2017 May 3.
9
The Role of Biomarkers in the Diagnosis and Risk Stratification of Acute Graft-versus-Host Disease: A Systematic Review.
Biol Blood Marrow Transplant. 2016 Sep;22(9):1552-1564. doi: 10.1016/j.bbmt.2016.04.022. Epub 2016 May 5.
本文引用的文献
1
High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation.
Blood. 2015 Jan 1;125(1):199-205. doi: 10.1182/blood-2014-06-584789. Epub 2014 Nov 6.
2
Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Biol Blood Marrow Transplant. 2014 Sep;20(9):1426-34. doi: 10.1016/j.bbmt.2014.05.023. Epub 2014 Jun 2.
3
Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes.
Biol Blood Marrow Transplant. 2014 Sep;20(9):1407-17. doi: 10.1016/j.bbmt.2014.05.022. Epub 2014 Jun 2.
4
Bone marrow mesenchymal stromal cells to treat tissue damage in allogeneic stem cell transplant recipients: correlation of biological markers with clinical responses.
Stem Cells. 2014 May;32(5):1278-88. doi: 10.1002/stem.1638.
5
The interleukin-1 family: back to the future.
Immunity. 2013 Dec 12;39(6):1003-18. doi: 10.1016/j.immuni.2013.11.010.
6
Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling.
J Clin Invest. 2013 Oct;123(10):4208-18. doi: 10.1172/JCI67119. Epub 2013 Sep 3.
7
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.
N Engl J Med. 2013 Aug 8;369(6):529-39. doi: 10.1056/NEJMoa1213299.
8
Discovery and validation of graft-versus-host disease biomarkers.
Blood. 2013 Jan 24;121(4):585-94. doi: 10.1182/blood-2012-08-355990. Epub 2012 Nov 19.
9
IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system.
J Clin Invest. 2007 Jun;117(6):1538-49. doi: 10.1172/JCI30634. Epub 2007 May 10.
10
Identification of serum soluble ST2 receptor as a novel heart failure biomarker.
Circulation. 2003 Feb 11;107(5):721-6. doi: 10.1161/01.cir.0000047274.66749.fe.
Zotero 插件